Comparison of the immunogenicity of ChAdOx1 nCoV-19 vaccine against the wild-type and delta variants in kidney transplant recipients and healthy volunteers
4
item.page.dc.date.issued
2022-05-01
item.page.dc.type
item.page.dc.identifier.issn
16006135
item.page.dc.identifier.eissn
16006143
item.page.dc.identifier.doi
item.page.dc.identifier.scopus
2-s2.0-85130003810
item.page.dc.identifier.pmid
35090091
item.page.oaire.citation.title
American Journal of Transplantation
item.page.oaire.citation.volume
22
item.page.oaire.citation.issue
5
item.page.oaire.citation.startPage
1459
item.page.oaire.citation.endPage
1466
item.page.dc.rights.holder
SCOPUS
item.page.dc.identifier.citation
American Journal of Transplantation Vol.22 No.5 (2022) , 1459-1466
punsarn.item.page.citation
Watcharananan S.P., Jaru-Ampornpan P., Sahawongcharoen S., Naitook N., Himananto O., Jongkaewwattana A., Setthaudom C., Rattanasiri S., Phuphuakrat A., Thakkinstian A., Mavichak V. Comparison of the immunogenicity of ChAdOx1 nCoV-19 vaccine against the wild-type and delta variants in kidney transplant recipients and healthy volunteers. American Journal of Transplantation Vol.22 No.5 (2022) , 1459-1466. 1466. doi:10.1111/ajt.16966 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/85906
item.page.dc.title
Comparison of the immunogenicity of ChAdOx1 nCoV-19 vaccine against the wild-type and delta variants in kidney transplant recipients and healthy volunteers
item.page.dc.contributor.author
item.page.oairecerif.author.affiliation
item.page.dc.contributor.other
item.page.dc.description.abstract
Little is known about immunogenicity after ChAdOx1 nCov-19 vaccination after transplantation. We assessed the vaccine response by antibody testing, surrogate neutralization test (sVNT) against wild-type (WT) and delta variant (DT), and T cell assay in 83 kidney transplant recipients (KTRs) and 52 healthy volunteers (HVs). For KTRs, a positive anti-RBD antibody was seen in 2.8% after one dose and 15.7% after two doses of the vaccine. After two doses, the positivity rate by sVNT was equal (4.9% each, for WT and DT) and was 13.4% by T cell response. Post two doses, KTRs had significantly lower geometric mean titer than HVs (1.93 [95% CI: 1.39–2.69] vs. 248.3 [95% CI: 203.7–302.6] BAU/ml, respectively, p <.001). Daily mycophenolate dose of ≥1000 mg significantly associated with negative seroconversion [risk ratio (RR) of 0.33, 95% CI: 0.15–0.72, p =.005]. Compared with cyclosporine, daily tacrolimus dose of ≤3 mg and >3 mg of tacrolimus significantly associated with negative seroconversion [RR = 0.38 (95% CI, 0.17–0.85, p =.018) and RR = 0.16 (95% CI, 0.37–0.73, p =.018)], respectively. The vaccine was safe and well-tolerated but the immune response after the two doses of ChAdOx1 nCov-19 vaccine in KTRs was very low.